Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Amarin To Present New Data Highlighting VASCEPA's Cardiovascular Benefits And EPA's Anti-Inflammatory, Antioxidant Mechanisms At AHA 2025

Author: Benzinga Newsdesk | November 03, 2025 08:41am

Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce the robust efficacy of VASCEPA®/VAZKEPA® (icosapent ethyl) in cardiovascular risk reduction (CVRR) as well as highlight the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA).

Data being featured at the AHA Scientific Sessions include new analyses from the REDUCE-IT study evaluating the clinical benefit of Icosapent Ethyl (IPE) on cardiovascular (CV) outcomes with or without baseline use of aspirin. Alongside this data is a series of mechanistic studies that explore the anti-oxidant effects of EPA on lipoprotein(a) [Lp(a)] as well as anti-inflammatory and endothelial-protective properties.

Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at AHA Scientific Sessions 2025 include:

Abstract Board Session

  • Efficacy of Icosapent Ethyl for Cardiovascular Risk Reduction by Aspirin Use in REDUCE-IT

    Rahul Aggarwal, Deepak L. Bhatt, Christie M. Ballantyne, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Jr., Jean-Claude Tardif, Gabriel Steg

    - Available November 9, 3:15 pm CST

    - Population Science Zone
  • Eicosapentaenoic Acid (EPA) Limits Lipoprotein(a) Oxidation and its Related Effects on Endothelial Cell Stress Response Protein Expression

    Samuel C.R. Sherratt, Peter Libby, Richard L. Dunbar, Deepak L. Bhatt, R. Preston Mason

    - Available November 10, 1:00 pm CST

    - Basic Science Zone

Moderated Digital Poster Presentations

  • Eicosapentaenoic Acid (EPA) and GLP-1 Receptor Agonist Combination Enhanced Expression of Src Kinase and Related Pathways in Endothelial Cells during Inflammation

    Samuel C.R. Sherratt, Peter Libby, Richard L. Dunbar, Deepak L. Bhatt, R. Preston Mason

    - Available November 9, 10:04 am CST

    - Basic Science Zone‚ Moderated Digital Poster 27
  • Eicosapentaenoic Acid Attenuates Oxidation of Lp(a) and other Atherogenic Lipoproteins by a Potent Scavenging Mechanism

    Samuel C.R. Sherratt, Peter Libby, Richard L. Dunbar, Deepak L. Bhatt, R. Preston Mason

    - Available November 10, 2:13pm CST

    - Basic Science Zone‚ Moderated Digital Poster 25

Posted In: AMRN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist